Jeito Capital Launches €1 Billion Fund to Back European Biotech Firms Targeted for Pharma Acquisitions

French venture capital firm Jeito Capital has announced the establishment of a €1 billion fund aimed at supporting European biotechnology companies. The fund will focus on identifying and investing in “plug-and-play” biotechs that are well-positioned for potential acquisitions by major pharmaceutical companies. This initiative seeks to provide growth capital to promising biotech firms, enabling them to advance their development pipelines and attract interest from larger industry players.

Jeito Capital’s strategy emphasizes targeting companies with strong scientific foundations and scalable platforms that can seamlessly integrate into the portfolios of global pharmaceutical corporations. By concentrating on these types of biotechs, the firm aims to bridge the gap between early-stage innovation and commercial viability. The €1 billion fund represents one of the largest commitments in Europe’s biotech sector, reflecting growing investor confidence in the region’s life sciences ecosystem.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 8, 2026

Author

GOAI